Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1

BACKGROUND: Interferon-free regimens to treat hepatitis C virus (HCV) genotype 1 are effective but costly. At this time, payers in the United States use strategies to control costs including (1) limiting treatment to those with advanced disease and (2) negotiating price discounts in exchange for exc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Linas, Benjamin P., Morgan, Jake R., Pho, Mai T., Leff, Jared A., Schackman, Bruce R., Horsburgh, C. Robert, Assoumou, Sabrina A., Salomon, Joshua A., Weinstein, Milton C., Freedberg, Kenneth A., Kim, Arthur Y.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Major Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5414108/
https://ncbi.nlm.nih.gov/pubmed/28480259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofw266
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars